S. C. Tamer

Efficacy and Safety of Insulin Degludec in a Flexible Dosing Regimen vs Insulin Glargine in Patients With Type 1 Diabetes (BEGIN: Flex T1): A 26-Week Randomized, Treat-to-Target Trial With a 26-Week Extension

C. Mathieu, E. Franek, D. Russell-Jones, 2013, The Journal of clinical endocrinology and metabolism.

Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I/II study.

D. Wallace, B. Rojkovich, S. Sierakowski, 2010, Arthritis and rheumatism.

40th EASD Annual Meeting of the European Association for the Study of Diabetes

B. M. Rasmussen, A. M. Foster, S. Bandinelli, 2004, Diabetologia.

Risk Mitigation Strategy for Concizumab Clinical Trials after Pause Due to Non-Fatal Thrombotic Events

Trine Høyer Rose, S. Seremetis, S. Tamer, 2020 .

Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion

B. Bode, M. Demissie, L. Hyveled, 2017, Diabetes technology & therapeutics.

Insulin degludec compared with insulin glargine in insulin‐naïve patients with type 2 diabetes: A 26‐week, randomized, controlled, Pan‐Asian, treat‐to‐target trial

P. Clauson, Y. Iwamoto, S. Yoo, 2013, Journal of diabetes investigation.

Adding fast‐acting insulin aspart to basal insulin significantly improved glycaemic control in patients with type 2 diabetes: A randomized, 18‐week, open‐label, phase 3 trial (onset 3)

H. Rodbard, M. Piletic, D. Tripathy, 2017, Diabetes, obesity & metabolism.

Insulin Detemir Results in Less Weight Gain than NPH Insulin When Used in Basal-Bolus Therapy for Type 2 Diabetes Mellitus, and this Advantage Increases with Baseline Body Mass Index

P. Clauson, K. Rašlová, S. Tamer, 2007, Clinical drug investigation.